en_USEnglish zh_CNChinese

Search the whole station

Kousai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held

Corporate News News Center 491

Shanghai, August 14, 2024 -- On today's sunny day, Shanghai Hengsai Bio-technology Co. The groundbreaking ceremony. The commencement of the project marks another important milestone for Hengsai Biotechnology in the field of biopharmaceuticals, and also signifies its continuous deep plowing and breakthrough in the field of cell therapy.

At 9:08 a.m., the groundbreaking ceremony was officially opened at Life Blue Bay, a new area in Lingang. (hereinafter referred to as "Lingang Fengxian"), Lv Jun, Vice Secretary of the Party Committee and General Manager, Wu Fumin, Vice Chairman and Deputy Secretary of Shanghai ITC, Cheng Xiangguo, Co-founder and Deputy General Manager of Hengsai Bio, Zhu Jincai, General Manager of Shanghai 3D Engineering, Yan Kun, Chairman of Zhenyue Fund, Liu Huawei, General Manager of Zhenchuanghui Incubator, Ji Zhaozhao. Yan Kun, Chairman of Zhenyue Fund Liu Huawei, General Manager of Zhenchuanghui Incubator Ji Zhaojia.

Lv Jun, Deputy Secretary of the Party Committee and General Manager of Lingang Fengxian CompanyHe delivered a warm speech, firstly, he expressed his warm congratulations on the smooth commencement of the project and expressed his heartfelt thanks to friends from all walks of life who have long supported and cared about the construction of the park. Mr. Lv pointed out that in recent years, with the rapid development of medical science and technology, the tumor treatment is gradually changing from traditional radiotherapy to the precision treatment with immune targeting as the core. As an important member of the body's immune system, the research and development of vaccine drugs for dendritic cells (DC) is regarded as an emerging pathway for anti-tumor treatment, with a broad application prospect. Since signing the contract to move into the park in early 2021, Hengsai Biological has not only successfully completed the pilot R&D project of Phase I DC vaccine, but also ushered in the commencement of the Phase II large-scale production project, which is undoubtedly another major breakthrough made by the company in the field of immunotherapy. Mr. Lv emphasized that the growth of Hengsai Biologicals in the park could not be separated from the hard work of every employee of Hengsai team and the support and help of our partners. In the future, Lingang Fengxian will continue to strengthen its service empowerment and work hand in hand with Hengsai Biologicals to jointly promote the subversive innovation of targeted drugs and bring more effective and safer treatment solutions for tumor patients.

 Dr. Liu Huining, Founder and CEO of Hengsai BiologicalsHengsai Bio focuses on the R&D and industrialization of DC vaccine, and has successfully completed the tasks of Phase I project through unremitting efforts. Today, the successful commencement of Phase II production and research project is not only an important point in the development course of Hengsai Biologicals, but also a key step towards the world's leading DC vaccine research and development enterprise. Hengsai Bio is confident that on the fertile land of Life Blue Bay in Lingang New Area, Hengsai Bio will rely on its institutional advantages and innovative environment to accelerate the project process and bring safer and more efficient immunotherapy products to patients around the world."

 Cheng Xiangguo, Co-founder and Deputy General Manager of Hengsai BiologicalsAt the groundbreaking ceremony, he delivered a speech: "Lingang Blue Bay, as the pioneer bearing area for biomedical industry in the new Lingang area, brings together all kinds of resource advantages and policy advantages, and provides the company with a broad space for development. We would like to thank the leaders at all levels of Lingang Fengxian Company for their support and assistance. We believe that under the care of leaders at all levels and the joint efforts of the project team, the Phase II production and research project will be completed on schedule and operated efficiently!"

Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatment.

Hengsai Bio's R&D center and pilot plant in Shanghai Lingang Blue Bay were put into use in 2021, and Zhongshan R&D center is under construction. The company's first pipeline KSD-101 has successfully completed the dual reporting in China and the United States, and is about to formally enter the registered clinical stage. The Company has now established stable partnerships with a number of domestic and international research institutions and tertiary hospitals to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and efficacy of the DC vaccine. Period completion and efficient operation!"

The prev. The next.

Related recommendations

Expand more!

en_US
zh_CN en_US